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http://dx.doi.org/10.1016/j.jacl.2013.05BACKGROUND: Omega-3 fatty acid (n-3 FA) biostatus can be estimated with red blood cell (RBC)
membranes or plasma. The matrix that exhibits the lower within-person variability and is less affected
by an acute dose of n-3 FA is preferred in clinical practice.
OBJECTIVE: We compared the acute effects of a large dose of n-3 FA on RBC and plasma levels of
eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA).
METHODS: Healthy volunteers (n 5 20) were given 4 capsules containing 3.6 g of n-3 FA with a
standardized breakfast. Blood samples were drawn at 0, 2, 4, 6, 8, and 24 hours. The EPA 1 DHA
content of RBC membranes and plasma (the latter expressed as a percentage of total FA and as a con-
centration) were determined. General linear mixed models were used to analyze the mean response
profiles in FA changes over time for plasma and RBCs.
RESULTS: At 6 hours after load, the plasma concentration of EPA 1 DHA had increased by 47%
(95% confidence interval [CI], 24% to 73%) and the plasma EPA 1 DHA percentage of total FA by
19% (95% CI, 4.7% to 36%). The RBC EPA 1 DHA percentage of composition was unchanged
[–0.6% (95% CI, 22.6% to 1.5%)]. At 24 hours, the change in both of the plasma EPA 1 DHA
markers was 10-fold greater than that in RBCs.
CONCLUSIONS: An acute dose of n-3 FA (eg, a meal of oily fish or fish oil supplements) taken
within a day before a doctor’s visit can elevate levels of EPA 1 DHA in plasma, whether expressed
as a percentage or a concentration, but not in RBC membranes. Similar to hemoglobin A1c, which
is not affected by an acute glycemic deviation, RBCs provide a more reliable estimate of a patient’s
chronic EPA 1 DHA status than does plasma.
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434 Journal of Clinical Lipidology, Vol 7, No 5, October 2013The Omega-3 Index is a validated biomarker of tissue
membrane omega-3 (n-3) polyunsaturated fatty acid
(PUFA) status.1 The test analyzes the level of eicosapentae-
noic acid (EPA) plus docosahexaenoic acid (DHA) in red
blood cell (RBC) membranes and expresses the result as
a percentage of total fatty acids (FAs). The choice of
RBCs was based on several factors, including previous lit-
erature that linked RBC EPA 1 DHA to risk of sudden car-
diac death,2 the ready availability of this biological
membrane in blood samples, and the high correlation
between RBC and myocardial EPA 1 DHA levels.3,4 In ad-
dition, RBCs are a more stable, within-person biomarker of
n-3 status than plasma, the latter having 4 times greater bi-
ological variability.5 Just as the RBC-based hemoglobin
A1c assay is a more stable marker of glycemic status than
fasting/fed serum glucose, the Omega-3 Index appears to
be a more stable marker of n-3 status than plasma-based
assays. Although stability has been documented over a
6-week period,5 the acute effects of a dose of EPA 1
DHA, whether from supplements or fish, on n-3 biostatus
has received only limited attention. A single dose of these
FAs clearly raises plasma EPA and DHA levels, peaking
at approximately 5 hours after administration,6 but the ef-
fect of such a dose on RBC EPA and DHA content are un-
known. The hypothesis tested in this study was that RBC
EPA 1 DHA levels would be less affected by an acute
load of n-3 FA than would plasma EPA 1 DHA levels.
There were both scientific and practical reasons for
undertaking this study. Scientifically, it is not known how
rapidly n-3 FA, on entering the plasma compartment in
chylomicrons, become incorporated into cell membranes.
Once in the nonesterified FA fraction, exchange is known
to occur between DHA and RBC membranes, beginning
approximately 8 hours after ingestion, with the predom-
inant delivery form being albumin-bound DHA-lysophos-
phatidyl choline,7 but the detailed time course in vivo is
not clear. From a practical point of view, now that medical
testing for n-3 FA status has become more common, cli-
nicians have a choice of whether to use RBC- or
plasma-based assays, and, for the latter, FA content can
be expressed as a percentage of total FA or as a concen-
tration. Different assays have different performance char-
acteristics, fasting requirements, and sensitivities to
perturbation with exogenous n-3 FA. Understanding these
issues can help clinicians choose the appropriate testing
method.Methods
Subjects
Inclusion criteria were healthy male and female sub-
jects of any race, older than 18 years, with body
mass index (BMI; calculated as weight divided by height;
kg/m2) between 18 and 35. Subjects were recruited by a
company-wide e-mail solicitation, and initially screenedby telephone interview. Subjects who had taken fish oil
supplements in the past 30 days, or who reported eating
.1 entree of ‘‘oily fish’’ (ie, salmon, herring, sardines, al-
bacore tuna, mackerel) per week over the prior month
were excluded. In addition, subjects with any known con-
dition that would impair fat absorption (eg, cystic fibrosis,
abetalipoproteinemia, chronic pancreatitis, pancreatic li-
pase deficiency syndrome) were also excluded. The first
20 subjects who qualified were e-mailed a copy of the in-
formed consent document (which had been approved by
the Copernicus Group Institutional Review Board). They
subsequently attended an initial visit at which time the
document was reviewed and informed consent was ob-
tained by signature.
Procedures
The initial laboratory visit took place in the morning
after at least an 8-hour fast at which time a baseline blood
sample was drawn. Immediately after the blood draw, the
subjects were given a standardized breakfast plus 4 enteric-
coated fish oil capsules, each containing 900 mg of EPA
(647 mg)1 DHA (253 mg; Simply Natural Triple Strength;
Sam’s Club). This dose provided a total of 3.6 g of EPA 1
DHA as ethyl esters, which is equivalent to the n-3 FA dose
one would get in approximately 6 ounces of farmed salmon.
It is also approximately the dose for n-3 acid ethyl esters
approved by the Food and Drug Administration; thus, there
were no safety concerns. Subjects returned to the laboratory
2, 4, 6, 8, and 24 hours after the test meal for subsequent
blood draws.
The standardized meals provided for breakfast, lunch,
and dinner (and evening snack) contained no fish, and
subjects were instructed to take no other fish oil pills during
the study. The food was provided on the basis roughly of
BMI, with subjects with a BMI , 27 receiving a total of
1800 kcal for the day and subjects with a higher BMI, 2200
kcal. Lunch and dinner were consumed after the blood
draws at 4 and 8 hours, respectively. The final sample was
drawn after a 10-hour overnight fast.
Laboratory methods
Blood was drawn into 5-mL ethylenediaminetetra-
acetic acid tubes and centrifuged immediately to separate
RBCs from plasma. Aliquots of packed RBCs and plasma
were transferred to cryovials and stored at 280C until
they were shipped on dry ice to OmegaQuant Analytics
(Sioux Falls, SD) for analysis. Total cholesterol and
triglycerides assays were performed with standard auto-
mated enzymatic methods on a Roche/Hitachi P-Modular
system with Roche reagents (Roche Diagnostics, Indian-
apolis, IN). Low-density lipoprotein cholesterol and high-
density lipoprotein cholesterol were measured with direct
enzymatic assays from Randox (County Antrim, United
Kingdom) on a Roche/Hitachi P-modular system. Plasma
glucose was measured with enzymatic methods on a
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sured by ion-exchange high-performance liquid chroma-
tography on a Bio-Rad Variant Turbo II, and complete
blood cell count was measured on Beckman Coulter Uni-
Cel DxH800.Table 1 Subject Characteristics (Men, n 5 2; Women,
n 5 18)
Mean SD Healthy Range
Age (y) 32 8.5 —
Race, n
African American 9 —
White 9 —
Asian 2 —
Total cholesterol (mg/dL) 185 47.5 ,200
LDL cholesterol (mg/dL) 113 46.9 ,130
HDL cholesterol (mg/dL) 58 13.9 $40
Triglycerides (mg/dL) 105 72.6 ,150
Non-HDL cholesterol (mg/dL) 128 46.8 ,130
Hemoglobin A1c (%) 5.3 0.4 #5.6
Glucose (mg/dL) 81 7.5 ,100
White blood cells (!103/mL)* 6.8 2.7 4.0 to 10.5
Red blood cells (!106/mL)* 4.5 0.4 4.1 to 5.6
Hematocrit (%)* 41 4.3 36 to 50
Hemoglobin (g/dL)* 13 1.4 12.5 to 17.0
Platelets (!103/mL)* 251 46.2 140 to 415
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
*n 5 17.FA analysis
Samples were thawed, and an aliquot of plasma was
combined (1:40 parts) with the derivatizing reagent [boron
trifluoride in methanol (14%), toluene, and methanol
(35:30:35 parts)], shaken, and heated at 100C for 45
minutes. After cooling, 40 parts of both hexane and
distilled water were added. After briefly vortexing, the
samples were spun to separate layers, and an aliquot of the
hexane layer that contained the FA methyl esters was
extracted. Diheptadecanoyl-phosphatidyl choline was in-
cluded in the plasma analysis as an internal standard for
calculating concentrations. RBCs were analyzed similarly
with the exception that only boron trifluoride in methanol
(14%) was used for derivatization, and the samples were
heated for only 10 minutes. Gas chromatography was
performed with 100-m SP-2560 column in a Shimadzu
2010 instrument equipped with a flame ionization detector
as described previously.8 FAs were quantified by 3-point
calibration curves and reported as percentage of composi-
tion (ie, each FA as a percentage of the total identified
FAs) for both plasma and RBCs, and, in addition, as a con-
centration (mg/mL) in plasma. Coefficients of variation
(CVs) for control samples were 2.5%, 2.0%, and 5.0%
for these analytes, respectively.
Statistical methods
General linear mixed models were used with estima-
tion to analyze the mean response profiles in FA changes
over time for plasma and RBCs. The responses over time
were all normalized to their baseline value, and because
the distribution was right-skewed, a natural log transfor-
mation was used to improve normality and homoscedas-
ticity of the residual errors. The repeated measures
covariance structure that minimized Akaike Information
Criterion9 was selected as follows: Toeplitz for plasma
concentration, first-order autoregressive for plasma per-
centage, and compound symmetry for RBC percentage.
The Toeplitz and autoregressive structures are banded,
with the later imposing a power lag function. The com-
pound symmetry structure provides a single correlation
between any 2 time points. The model parameter esti-
mates were exponentiated and reported as percentage of
changes from baseline. To determine which time points
were different from baseline for each sample type, Dun-
nett adjustment was used to control for multiple compar-
isons. Dunnett adjusted P values , .05 were considered
statistical significance. Analyses were performed with
SAS software version 9.3. (SAS Institute).Results
A total of 20 volunteers participated in this study. All
laboratory values were within normal ranges (Table 1). The
mean total energy consumed for the study day was
1936 G 80.4 kcal, and the mean total fat intake was
66 G 4.3 g (or 31% of kilocalories). A total of 19% of
the day’s kcal and fat (ie, 362G 77 kcal and 13G 4 g, re-
spectively, excluding the kilocalories and fat from the sup-
plements) were consumed at breakfast when the fish oil
capsules were taken.
Baseline levels of the 5 major classes of FA (saturated,
monounsaturated, n-6 and n-3 PUFAs, and trans) are pre-
sented in Table 2 along with the EPA 1 DHA values.
The within-subject and between-subject variability (both
expressed as the CV) differed substantially for each FA
class by sample type. FA levels in RBCs had approximately
2-fold lower between-person variability than did plasma FA
(percentage) for saturated, monounsaturated, and n-6
amounts; however, they were similar for n-3 PUFAs and
trans FAs. Greater variability was observed in concentra-
tions than in relative amounts. For example, the CV for sat-
urated FAs expressed as concentrations was approximately
14-fold higher than the CV for this class in RBC mem-
branes. For monounsaturated FAs, the CVs of these 2 ex-
pressions of FA status differed by 5-fold, and for the n-6
PUFA class, by 6-fold. For the n-3 PUFA the between-
person variability across sample types was similar.
Compared with the RBC-based metric, the within-person
variability for the plasma percentage-based metric was
2- to 5-fold higher for all FA classes except trans FA, which
was 10-fold higher. For the plasma concentration-based
metric, it was 5- to 8-fold higher for all FA classes except
Table 2 Abundance and Variability of Major FA Classes by Sample Type (n 5 20)
Saturated Monounsaturated Omega-6 PUFA Omega-3 PUFA trans FA EPA 1 DHA
Red blood cell
Mean (% of total FA) 40.4 13.4 36.9 7.5 1.4 4.8
SD (% of total FA) 0.9 1.2 1.5 1.6 0.3 1.5
Within subject CV (%)* 1.5 1.4 2.0 2.7 1.8 3.1
Between subject CV (%) 2.3 9.0 4.0 21.4 21.2 31.8
Plasma
Mean (% of total FA) 28.4 20.4 45.8 3.5 1.1 2.3
SD (% of total FA) 1.7 3.3 4.1 0.9 0.3 0.8
Within subject CV (%)* 3.3 5.9 3.4 11.6 18.1 15.7
Between subject CV (%) 5.9 16.3 9.1 25.0 29.9 34.7
Plasma
Mean (mg/mL) 834.2 613.6 1325.5 98.9 33.3 64.1
SD (mg/mL) 260.4 277.9 334.5 27.1 13.0 20.8
Within subject CV (%)* 12.1 14.9 9.2 16.7 21.9 19.3
Between subject CV (%) 31.2 45.3 25.2 27.4 39.1 32.4
CV, coefficient of variation; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; FA, fatty acid; PUFA, polyunsaturated fatty acid; SD, standard
deviation.
*Within-subject CV was calculated over the 6 time points; all other measures are at baseline.
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higher.
For the FA metric of primary interest in this study,
EPA 1 DHA, the individual subject data (and group means
with 95% confidence interval [CI]) for all 3 sample types
across the 24-hour period are shown in Figure 1. When
expressed as percentage of changes from baseline, both of
the plasma-based metrics showed significant increases
over the study period, but the RBC-based metric did not
(Fig. 2). At 6 hours after load, the plasma concentration
of EPA 1 DHA had increased by 47% (95% CI, 24% to
73%), the plasma EPA 1 DHA as a percentage of total
FA by 19% (95% CI, 4.7% to 36%), and the RBC
EPA 1 DHA percentage composition by 20.6% (95%
CI, 22.6% to 1.5%). At 24 hours all sample types had sig-
nificant increases in EPA 1 DHA of 28%, 30%, and 2.8%,
respectively.
Discussion
The purpose of this study was to compare the response
of plasma-based with RBC-based markers of n-3 FA status
to a pharmacologic dose of n-3 FAs. We found that the
24-hour excursion for plasma (expressed as both percentage
and concentration) was significantly greater than that for
RBCs. In plasma the peak n-3 FA concentration was
observed at 6 hours, whereas the peak as a percentage of
total FA was seen at 24 hours. RBC EPA 1 DHA levels
were increased from baseline only at 24 hours, but by an
order of magnitude less than plasma (approximately 3% vs
30% elevated).
In a previous study we examined the within-person
biological variability in EPA1 DHA by sample type over 6
weeks in volunteers with a stable n-3 FA intake.5 EPA 1
DHA levels as a percentage of total FA were 10 timesless variable when measured in RBCs (CVwithin 5 1.3%)
than in plasma (CVwithin 5 13.6%) (Fig. 3). These values,
measured over weeks, were similar to those observed
here (2.7% and 15.7%, respectively) which were measured
over hours after a large n-3 FA load. Despite the differences
in within-person variability, the mean levels for both (fast-
ing) plasma and RBCs were stable over that 6-week study.
Therefore, in research studies done in large populations, ei-
ther metric can provide an estimate of n-3 FA status, but in
the clinical setting, where visit-to-visit comparisons are
most important, the RBC-based metric is preferred. An-
other problem with plasma-based metrics is their sensitivity
to fasting status. In the earlier study,5 the effects of a high-
fat meal (with no fish oil) on EPA 1 DHA levels in RBCs
and plasma (again, both expressed as a percentage of total
FA) were assessed. Four hours after the meal, no change
was observed in the RBC metric, but an 11% decrease
(P 5 .05) was seen in the plasma metric. The latter was
caused by the increase in FAs from the meal in the plasma
which reduced the n-3 fraction as a percentage of the total.
In the present study, the percentage of EPA 1 DHA in
plasma increased by approximately 20% after the meal.
This is because a large amount of n-3 FA was given with
the test meal. Although a large dose of EPA 1 DHA as
given here can begin to affect the RBC level after 24 hours,
it generally takes 12 to 16 weeks for the EPA 1 DHA level
in RBCs to reach a new steady state after a sustained in-
crease in intake10; plasma (phospholipid) levels stabilize
in approximate 6 weeks.11 The findings of the present study
compliment these longer term data and indicate that the
RBC-based metric is not only more stable over time
when n-3 FA intake is unchanging but is also essentially
unaffected by an acute dose of n-3 FA.
The difference in the FA composition of plasma and
RBCs is well known.12–14 Relative to the former, the latter
Figure 1 Effects of a single dose of EPA 1 DHA (3.4 g) taken
with breakfast on absolute EPA 1 DHA levels in plasma (ex-
pressed as a percentage of total fatty acids, top; and expressed
as concentrations, middle) and in RBCs (expressed as a percent-
age of total fatty acids; bottom) over 24 hours. Individual patient
responses (n 5 20) are shown (gray lines) and group means with
95% confidence intervals (black lines). DHA, docosahexaenoic
acid; EPA, eicosapentaenoic acid; RBC, red blood cell.
Figure 2 Effects of a single dose of EPA 1 DHA (3.4 g) taken
with breakfast on the percentage of change from baseline (hour 0)
in EPA 1 DHA levels in plasma (expressed as a percentage of to-
tal fatty acids, top; and expressed as concentrations, middle) and
in RBCs (expressed as a percentage of total fatty acids; bottom)
over 24 hours (n 5 20). Mean estimate and 95% Dunnett-
adjusted confidence intervals are shown. *Difference from base-
line, P, .05. DHA, docosahexaenoic acid; EPA, eicosapentaenoic
acid; RBC, red blood cell.
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branes, they are comprised almost entirely of phospho-
lipids, the lipid class that carries the greatest proportion
of long-chain PUFAs.12 With respect to their responses to
changes in n-3 FA intakes, all blood-based pools (and car-
diac tissue3,4) become enriched with higher intakes to
roughly equal extents.15
Although recent meta-analyses of randomized trials
have questioned the value of n-3 FA supplementation for
reducing the risk of coronary heart disease,16,17 the epide-
miologic evidence for a benefit from higher intakes of
n-3 FA (which are better correlated with RBCs than
plasma18) are robust.19,20 Indeed, several studies have spe-
cifically linked RBC n-3 FA levels with cardiovascular dis-
ease (CVD) outcomes. Most notably, in 1995 Siscovick
et al2 were the first to document a strong correlation with
RBC EPA 1 DHA and primary cardiac arrest. In 2002, Al-
bert et al21 showed that whole blood EPA1 DHA (which is
highly correlated with RBC levels1) was an independent
predictor of risk of sudden cardiac death. Building on thisfoundation, the Omega-3 Index was proposed in 2004 as
a marker of risk of death from CVD.1,22 This particular as-
say method has now been widely used in a variety of stud-
ies that examined not only CVD but also depression and
cognitive function.23–39 Others that used different analytical
methods have reported RBC n-3 FA associations with other
conditions. For example, in a large cohort in China, RBC
DHA was strongly and inversely associated with risk of
multiple forms of chronic disease.40 RBC FA patterns
have been related to atrial fibrillation,41 longevity,42 liter-
acy/attention deficit hyperactivity disorder,43 breast cancer
in Japan,44 prostate-specific antigen levels in Jamaica,45
cognitive function,46,47 hostility,48 eating disorders,49 and
dyslexia.50 Relatively few studies have examined the rela-
tions between plasma FA percentage of composition and
CVD outcomes, and most studies have come from Ja-
pan.51–58 Only one study has compared the percentage of
composition of n-3 FA in plasma and RBCs as predictors
of coronary heart disease, in this case for nonfatal myocar-
dial infarction.58 The former was generally better than the
Figure 3 Levels of EPA 1 DHA in whole plasma (upper) and
RBCs (lower; both in percentage of composition) measured in
the fasting state once a week for 6 weeks in 21 healthy volunteers.
DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; RBC,
red blood cell. Data from Harris and Thomas.5
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that were roughly equal, which is highly suspect as DHA is
typically 6-8 fold higher than EPA in RBCs (24-26). This
suggests co-elution of a contaminant with EPA in the anal-
ysis, making the RBC data questionable in this study. A re-
cent study from the Cardiovascular Health Study that
focused on plasma phospholipid n-3 FA percentage (an-
other analyte that correlates well with the RBC metric15)
reported a significant inverse relationship between n-3 FA
levels and total mortality.59
As alluded to earlier, many of the RBC-based studies23–39
have used the identical laboratorymethod,8whereas a variety
of methods were used in the plasma-based studies. Without
formal interlaboratory comparison, there is no guarantee
that values with onemethod will agreewith values of another
method; even RBC-based methods vary in output.60 It has
been shown that methodologic differences in just the pre-
chromatography phase of FA processing can lead to different
values.61
The results of this study have practical implications. For
example, most patients are told to increase their intake of
oily fish or to start taking fish oil supplements after a blood
test reveals suboptimal n-3 FA levels. Although some will
comply, others will not but may choose to take a single
large dose of fish oil within 24 hours before their appoint-
ment in an effort to improve their blood levels and thereby
appear to have been compliant. When their blood is drawn
at the appointment, their plasma EPA 1 DHA level will
indeed be elevated and could easily mislead the physician,
but the RBC level should be unchanged, reflecting the true
chronic condition.Finally, there is a place for both plasma and RBC n-3 FA
analyses (and for whole blood, if it is the only sample type
available21,28). As noted earlier, both could potentially be
used in population research studies (if fasting status is
known) because mean levels are reasonably stable, and these
2 markers are well correlated (particularly as percentages,
r5 0.90; not as well for RBC percentage vs plasma concen-
tration, r5 0.73; unpublished observations). Plasma also re-
sponds more quickly to a change in n-3 FA intake than does
the RBC pool.11 The RBC method, however, has at least 4
characteristics that favor its use in the clinical setting: low
within-subject variability, resistance to artificial elevation
after an acute n-3 FA dose, much longer half-life,10 and in-
sensitivity to fasting status. In addition, the amount of pub-
lished research that links RBC n-3 FA levels with
clinically relevant outcomes is greater than that for plasma.
Hence, RBC-based therapeutic targets have a clinical rele-
vance not enjoyed by plasma-based targets.Conclusion
In conclusion, the RBC fraction appears to be the
preferred sample type for the assessment of n-3 FA
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